Category: Biotech
-
Zentek (ZEN.V) took a years long path to figure out its incredible biotech potential
Today I found myself going down an investment rabbit hole, chasing information about a company that, to be honest, is wallowing, and has for a while. Unmarketed. Unexplained. Unsimple. Unloved. The company is Zentek (ZEN.V). Back in the day, it was an exploration play known as Zen Graphene Solutions that was more focused on developing…
-
Explaining biotech: Bionxt Solutions (BNXT.C) advances MS product through animal study
Bionxt Solutions Inc. (BNXT.C) has finished a study on a new type of medicine strip that dissolves in your mouth. This strip is designed to treat multiple sclerosis (MS), a condition that affects the brain and nerves. The study looked at how well and how quickly the body absorbs the medicine from this strip compared…
-
Lophos Pharma (MESC.C) now readies for natural and synthetic peyote production
Lophos Pharmaceuticals Corp. (MESC.C), a key player in the Canadian biosciences/psychedelics sector, has made a significant leap forward in the field of psychoactive compound research and development as it has announced the successful finalization of a new synthetic mescaline production protocol, marking a major milestone in the accessibility and study of psychoactive substances. This development…
-
InnoCan Pharma’s (CSE: INNO) investment potential in the Pharmaceuticals Sector: A Balanced View
InnoCan Pharma Corporation, trading on the Canadian Securities Exchange under the symbol INNO, FSE: IP4, and OTC: INNPF, is a pharmaceutical technology company that has garnered attention in the investment community. This article evaluates its potential as an investment option in the pharmaceuticals space, considering both its recent achievements and challenges. Business Model and Strategic…
-
Revive Therapeutics (RVV.C) finds multiple research options moving forward
In Canada, if you look backwards over the timeline, you’ll often find public companies have been other things back in the day. Risen, fallen, tapped out, rolled back, reemerged as a whole new thing. Sometimes this happens several times before a business model catches. Revive Therapeutics (RVV.C) is that rare Canadian smallcap that, while it…
-
Perimeter Medical Imaging AI (PINK.V): After 3 years, it’s half-priced, AI-based, and in FDA trials
If you’ve been around here for a while, like going back three years or so ago, you may recall a former client company in Perimeter Medical Imaging (PINK.V). I really loved repping PINK, because sometimes it’s nice to be able to say that you really ARE trying to cure cancer, and make some profit while…
-
Lucy Loves Luchre: Medexus Pharmaceuticals (MDP.T) is growing fast, keeping the bottom line trim
Hey y’all, Lucy Copperpot back for more analysis of Equity.Guru companies – this one is no longer on the client list, but I asked for permission to dig in anyway because I really think a ton of risk has been removed from Medexus Pharmaceuticals (MDP.T) that the market hasn’t factored in, and that’s a real…
-
Revive Therapeutics (RVV.C) licenses patent on long COVID biomarkers
Revive Therapeutics (RVV.C), a company that specializes in creating treatments and tests for diseases that don’t have many existing options available, has made a deal with a health research group called Lawson Health Research Institute to license the rights to use special signals in the blood—called biomarkers—that can show if someone has ‘long COVID.’ “We…
-
Revive Therapeutics (RVV.C): Covid came, Covid went, but Revive is still fighting
Back at the dawn of Covid-19, a load of public companies started pumping out news releases that claimed they were going to be entering the medical space. In the best tradition of Howe Street, long dormant mining companies suddenly became med-tech deals, hawking everything from clear plastic checkout counter dividers to virus sniffing doorways to…
-
Core Story: FendX Technologies (FNDX.C) repels and kills pathogens and viruses
We went after this company as a client because there are three things about it that make me swoon. 1: The CEO has done it all before, in this industry, and has more knowledge about her domain than most 2: The product is needed, necessary, cutting edge, and quickly developing with their academic partners 3:…